Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis

Abstract

Get full access to this article

View all access options for this article.

References

Stokes

Foster

Markowitz

, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400–1406.

Ramos-Casals

Brito-Zerón

Muñoz

, et al. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242–251.

Piga

Chessa

Ibba

, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort. Autoimmun Rev 2014; 13: 873–879.

Parekh

Ching

Rahman

Stamp

. Onset of Wegener’s granulomatosis during therapy with golimumab for rheumatoid arthritis: A rare adverse event? Rheumatology 2010; 49: 1785–1787.

Wilkerson

Hazey

Bahrami

Callen

. Golimumab-exacerbated subacute cutaneous lupus erythematosus. Arch Dermatol 2012; 148: 1186–1190.

Brunasso

AMG

Aberer

Massone

. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus 2014; 23: 201–203.

Aringer

Smolen

. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202–202.

Araújo-Fernández

Ahijón-Lana

Isenberg

. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus 2014; 23: 545–553.